STOCK TITAN

Eterna Therapeutics Inc. - $ERNA STOCK NEWS

Welcome to our dedicated page for Eterna Therapeutics news (Ticker: $ERNA), a resource for investors and traders seeking the latest updates and insights on Eterna Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eterna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eterna Therapeutics's position in the market.

Rhea-AI Summary
Eterna Therapeutics appoints Dorothy Clarke to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.9%
Tags
none
-
Rhea-AI Summary
Eterna Therapeutics Inc. has appointed Brant Binder and Richard Wagner, Ph.D. to its Board of Directors, while Charles Cherington and Nicholas Singer have stepped down. Binder and Wagner bring a wealth of industry expertise and have a proven history of delivering value for stakeholders. Eterna looks forward to working with them to drive future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
management
-
Rhea-AI Summary
Eterna Therapeutics and Factor Bioscience present new data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting at ASGCT Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
Rhea-AI Summary
Eterna Therapeutics Inc. has acquired the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition includes Exacis' pipeline of engineered cell therapy programs for hematologic and solid tumors. Eterna now has an exclusive global license to produce mRNA-engineered natural killer and T-cell therapies derived from induced pluripotent stem cells. The terms of the acquisition include an upfront payment in shares of Eterna common stock, as well as milestone and other potential payments totaling up to $49.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
Eterna Therapeutics Inc.

Nasdaq:ERNA

ERNA Rankings

ERNA Stock Data

10.01M
2.95M
39.31%
16.19%
0.78%
Television Broadcasting
Information
Link
United States of America
CAMBRIDGE

About ERNA

brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. brooklyn’s most advanced program is irx-2, a human cell-derived cytokine therapy, studying the safety and efficacy of irx-2 in patients with head and neck cancer in phase 2b. in a phase 2a clinical trial in head and neck cancer, irx-2 demonstrated an overall survival benefit. additional studies are either underway or planned in other solid tumor cancer indications. brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. for more information about brooklyn and its clinical programs, please visit www.brooklynitx.com.